Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?

Lorenzo Calvetti, Giuseppe Aprile


In the last two decades, the clinical application of different antiangiogenic drugs has improved the outcome of most solid tumors. In particular, gastrointestinal and lung cancers are commonly treated with antiangiogenic drugs, either alone or combined with standard chemotherapy. Since their introduction in clinical practice, the need for novel radiological patterns of response to antiangiogenics have early emerged, as a consequence of a distinctive mechanism of action (1).